Background-In a number of coronary bifurcation lesions, both the main vessel and the side branch need stent coverage.
B ifurcation lesions occur in about 15% of percutaneous coronary interventions (PCI). 1 In these lesions, balloon angioplasty without stenting had a high risk of acute vessel closure. 2 Furthermore, implantation of bare metal stents (BMS) was associated with over 30% rate of major adverse cardiac events (MACE) at 1 year in a registry study. 3 Another study found over 30% rate of target lesion revascularization at 6 months follow-up both with 1 and 2 BMS techniques. 4 The use of sirolimus eluting stents (SES) has been reported to reduce restenosis in simple and in complicated coronary lesions. [5] [6] [7] [8] [9] [10] SES implantation in bifurcation lesions has been very promising with low clinical and angiographic event rates, both after procedures with stenting of the main vessel (MV) only and in procedures where both MV and side branch (SB) were stented. 5, 11, 12 At present, the general recommended stenting strategy in coronary bifurcation lesions is the provisional SB stenting strategy. 13 With this strategy, the MV is stented, whereas the SB is only treated with stent implantation in case of significant residual SB stenosis after stenting of the MV. However, a number of coronary bifurcation lesions need stent treatment of both the SB and the MV. Therefore, to provide stent coverage of the entire bifurcation region, dedicated bifurcation stent techniques have been proposed. Among those, the crush 14 and the culotte 15 techniques are currently used in clinical practice and have been associated with promising clinical and angiographic outcome. 11, 16 The present study is the first randomized clinical and angiographic comparison of the crush and the culotte bifurcation stent techniques.
Methods

Patients and Study Design
This nonblinded randomized multicenter trial was conducted at 13 cardiology centers in Denmark, Finland, Norway, and Latvia. From August 2005 to February 2007 a total of 424 patients were enrolled. On the basis of the total PCI volumes of the participating centers, the number of eligible patients was estimated to 2292 patients. The primary reason for not enrolling in the study was differences in inclusion rates among operators. A flow diagram of the study is shown in Figure 1 . Ethics committees in all participating countries approved the protocol, and all participating patients gave written informed consent.
Men and women, aged 18 years or older, with stable or unstable angina pectoris or silent ischemia and a de novo coronary bifurcation lesion were considered eligible for enrolment. A bifurcation lesion was defined according to Lefevre et al 17 and could be located in the left anterior descending artery and a diagonal, the circumflex artery and an obtuse marginal, the right coronary artery and posterior descending artery/postero-lateral artery or the left main stem/circumflex artery/left anterior descending artery in a right dominant system. The diameter of MV had to be Ն3.0 mm and of SB Ն2.5 mm by visual estimate. Exclusion criteria were ST-elevation acute myocardial infarction (AMI) within 24 hours, life expectancy less than one year, s-creatinine Ն200 mol/L and allergy to any of the drugs used (aspirin, clopidogrel, ticlopidine, sirolimus, and paclitaxel).
Randomization
Randomization was performed in blocks for each participating hospital, 1:1 by computerized assignment with stratification according to sex, diabetes, age Ͼ70 years, use of glycoprotein receptor antagonists, and consent to angiographic follow-up. An automatic telephone randomization/voice-response system was used. Patients were randomized before any balloon dilatation was performed.
Stent Implantation
Patients were pretreated with aspirin (75 mg) and clopidogrel (300 mg). Heparin was administrated according to local hospital routine, and ACT control was not mandatory. Glycoprotein receptor antagonists were used at the discretion of the operator. Aspirin was continued indefinitely, clopidogrel for 6 to 12 months according to local practice. Ticlopidine could be used if the patient did not tolerate clopidogrel.
The operator was requested to avoid pretreatment (conventional balloon or cutting balloon) of segments not covered by stent. The SES, "Cypher Selectϩ" coronary stent (Cordis/Johnson & Johnson, Miami Lakes, Fla) was used in the study.
Main treatment principles of the crush technique are as follows: (1) wiring of MV and SB, (2) optional predilatation of MV and/or SB, (3) stenting of SB with uninflated stent or balloon in MV and with proximal end of SB stent at the center of the MV, (4) SB wire and stent balloon removed, (5) crushing of SB stent with MV balloon or stent, (6) in balloon crush, stenting of MV and rewiring of SB through MV stent, and (7) procedure finalized by kissing balloon dilatation.
Main treatment principles of the culotte technique are as follows: (1) wiring of MV and SB, (2) optional predilatation of MV and/or SB, (3) stenting of MV, (4) rewiring of SB through MV stent, (5) stenting of SB through MV stent, (6) rewiring of MV through SB stent, and (7) procedure finalized by kissing balloon dilatation.
Implantation of additional stents to cover the whole lesion or to cover a dissection was allowed. If the study stent could not be delivered, another drug eluting stent or a BMS was allowed. Different types of drug eluting stents in the same vessel were not allowed. Both operator and patient were aware of the assigned treatment.
Cardiac Biomarkers and ECG
CK-MB mass, Troponin-T or Troponin-I were measured at the time of the procedure and after 12 to 18 hours. Troponin-T was used as the primary marker, CK-MB mass or Troponin-I only if Troponin-T was not available. To avoid confounding nonprocedure-related marker elevation, patients with unstable angina pectoris were included in the biomarker analysis only if preprocedure and postprocedure markers were normal. Marker elevation of more than or equal to 3 times upper limit of normal was considered significant. A 12 lead ECG was obtained before and 12 to 18 hours after the procedure.
Follow-Up
For safety reasons, total death and MACE were recorded by telephone call after 1 month. There was a clinical follow-up visit after 6 months for primary end-point registration. An 8-month control coronary angiography was scheduled at randomization in patients who consented herein. No patients were lost to clinical follow-up.
Quantitative Coronary Angiography at Eight Months
Coronary angiograms obtained at baseline, at completion of the stenting procedure, and after 8 months, were submitted to 1 of the 2 angiographic core laboratories (Aarhus University Hospital, Skejby, Aarhus, Denmark or Paul Stradins Clinical Hospital, Riga, Latvia) and were analyzed with the use of a computer-based system dedicated to bifurcation analysis (Qangio XA version 7.0, Medis, Leiden, The Netherlands). Quantitative angiographic measurements of the bifurcation lesion were obtained in the following 3 segments: the proximal MV segment, the distal MV segment, and the SB. In the MV and the SB segments, measurements were obtained in the stents and in the margins 5-mm proximal and distal to the stents (edge). The analyses were not blinded.
Definitions
Total death; death for any reason. Cardiac death; death was considered cardiac unless other cause documented. Nonprocedure-related MI, a rise of biochemical markers exceeding the decision limit of myocardial infarction (above the 99th percentile) for a reference population provided an coefficient of variation of Ͻ10%) with at least one of the following: (1) ischemic symtomps; (2) ECG changes indicative of ischemia (ST segment elevation or depression; (3) development of pathological Q-wave; and (4) no relation to a PCI procedure. Stent thrombosis (definite, possible, and probable) was defined according to the ARC criteria. 18 Target lesion revascularization is defined as repeated revascularization by PCI or surgery of the target lesion. Target vessel revascularization is defined as repeated revascularization by PCI or surgery of the target vessel. Percent diameter stenosis is calculated as (reference diameterϪminimal luminal diameter)/reference diameterϫ100. Restenosis is Ͼ50% diameter stenosis at 8 months angiographic follow-up. Late lumen loss is postprocedure minimal luminal diameterϪminimal luminal diameter in millimeters at 8 months follow-up. Procedural success is residual stenosis Ͻ30% and TIMI flow III in MV and SB after the index procedure.
Study End-Points
The primary end-point of the study was the clinical combined end-point of MACE; cardiac death, nonprocedure-related myocardial infarction, stent thrombosis, or target vessel revascularization by PCI or coronary artery bypass surgery after 6 months.
Secondary end-points were as follows: (1) individual end-points of total death, cardiac death, nonprocedure-related myocardial infarction, target lesion revascularization, and target vessel revascularization; (b) procedure-related biomarker increase (rise of biochemical markers exceeding Ͼ3 times the decision limit of myocardial infarction [99th percentile including Ͻ10% cardiovascular] of Creatine Kinase-MB (CK-MB) mass, Troponin-T, and/or Troponin-I); (c) the angiographic end-point of significant in-segment and in-stent restenosis (Ͼ50% diameter stenosis) of MV and/or SB. The study was monitored by the PCI-Research Unit, Aarhus University Hospital, Skejby. An independent end-point committee, chaired by Kristian Thygesen, MD, Aarhus University Hospital, Aarhus, Denmark adjudicated the clinical study end-points blindly.
Statistical Analysis
Power calculations of the present study were problematic because there were no available clinical end-point data on culotte stenting and limited data on crush stenting using DES. We based our power calculations on an expected primary end-point event rate of 25% in the culotte group, alpha 5%, power 80%, and using a 2-sided 2 test. To detect a reduction in primary end-point rate to 13%, 167 patients would be needed in each group. Because of considerable uncertainty in expected end-point rates in drug-eluting stents (DES)-treated bifurcation lesions, it was decided to include 200 patients in each group. 5 Differences in categorical variables between the 2 groups were analyzed using the 2 test or Fisher's exact test. Continuous variables were analyzed using the Student's t test and time to event data using the Kaplan-Meier method and the log-rank test. All probability values were 2-sided. Level of significance was 5%. The analysis was performed on an intention to treat basis. All analyses were performed using SPSS 13.0 (SPSS Inc, Chicago, Ill).
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Results
Baseline Characteristics and Procedural Data
The 2 groups were well balanced regarding baseline clinical characteristics and risk factors with the exception that more patients in the crush group were treated for hypercholesterolemia. In three fourths of the cases, the indication for treatment was stable angina pectoris and in one fourth unstable angina pectoris. In few patients the indication was silent ischemia. The use of aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors was similar in the 2 groups (Table 1) . Procedural data are shown in Table 2 . The index lesion location was the left anterior descending artery in 64%, the circumflex artery in 20%, the right coronary artery in 6%, and the left main stem in 10%, with no difference between the groups. There were more patients with significant stenosis in both MV and SB, ie, a "true" bifurcation lesion (Medina classification 1,1,1; 1,0,1; 0,1,1), 19 in the culotte group than in the crush group (82.3% versus 73.3%, Pϭ0.03). The SB had no significant stenosis in 13.0% of crush patients versus 18.6% of culotte patients (ns). Vessel size and stenosis severity as assessed by the operator were similar in the 2 study groups. SB angulation of Ͻ70°was seen in 64.4%, calcification in 26.9%, and proximal tortuosity in 5.8% of the lesions, with no difference between the groups. Procedure time, fluoroscopy time, and volume of contrast used were similar in the 2 groups. Also, the number of stents implanted in the index lesion, the rate of stenting of MV and SB, treatment success rate and rate of treatment according to randomization were similar in the 2 groups ( Table 2 ). The SB was predilated more often in culotte-stented lesions. A final kissing balloon dilatation was performed in significantly less of the patients in the crush than in the culotte group (Table 2) . Cypher Selectϩ was the study of stent. Few other stents were used; another drug eluting stent was implanted in 3.3% and 2.1% and a BMS in 2.5% and 1.5%, in the MV and in the SB, respectively, with no difference between the study groups.
Clinical Outcome
The rate of event free survival for the primary end-point, MACE (cardiac death, MI, target vessel revascularization, stent thrombosis) after 6 months follow-up is shown in Figure  2 . There was no significant difference in the 6-month MACE rate between the 6 groups (4.3% in the crush and 3.7% in the culotte group, Pϭ0.87). The individual end-points after 6 months are shown in Table 3 . The rates of individual end points were low in both groups without significant difference between the groups.
Procedure-Related Elevation of Biomarkers
Procedure-related biomarker release could be evaluated in 296 patients (148 patients in both groups). A marker elevation exceeding 3 times the decision limit of myocardial infarction was seen in 15.5% of crush-stented patients and in 8.8% of culotte-stented patients (Pϭ0.08).
Quantitative Coronary Angiography Analysis
At randomization, 373 patients were scheduled for an 8-month follow-up angiography. Complete angiographic evaluation was available in 324 (88%) patients; of these, 160 patients were randomized to crush and 164 patients to culotte stenting. A major reason for not having 8 months angiographic follow-up was the extremely long distances to interventional centers in the northern part of Scandinavia. Insegment and in-stent QCA data (reference diameter, minimal luminal diameter, percentual stenosis, and late loss) were similar in the 2 groups (Table 4 ). There was a trend to less in-segment restenosis at 8-month follow-up ( Figure 3 ) because of significantly reduced SB in-stent restenosis in culotte-treated patients ( Table 4 ). In-stent restenosis of MV and/or SB after 8 months was found in 10.5% versus 4.5% (Pϭ0.046) in the crush and culotte groups, respectively.
Discussion
In this first randomized comparison of the crush and the culotte bifurcation stenting techniques using SES, we found low and similar 6-month clinical event rates in both study groups. At 8-month angiographic follow-up, rates of in-lesion restenosis were low in both groups. There was a trend toward less restenosis of the entire bifurcation lesion because of significantly reduced SB in-stent restenosis in patients treated with the culotte technique. In PCI, bifurcation lesion treatment without stenting or with BMS used to be associated with high risk of complications and restenosis. [1] [2] [3] [4] The use of drug eluting stents and introduction of different bifurcations stenting strategies and techniques resulted in marked improvements. 5, 6, 12 Thus, the recently published ARTS II study 20 had similar event rates in bifurcation and nonbifurcation lesions. At present, a strategy of optional SB stenting, where the SB is stented only in case of severe stenosis or flow problems after MV stenting, has been found to be safe and efficient in registries and randomized clinical and angiographic trials. 5,11,12,21 However, it is still an open question if the strategy of optional SB stenting should be the preferred treatment in all bifurcation lesions, especially if the bifurcation lesion encompasses a large SB or there is a long lesion of the SB. We selected crush and the culotte bifurcation techniques for the present evaluation. These techniques are dedicated bifurcation techniques aiming at full stent coverage of the bifurcation lesion, based on extensive documentation of low in-stent restenosis rates in DES-treated lesions. 18 The culotte technique was described by Chevalier et al 15 using BMS. Originally, they recommended to stent the branch with the sharpest angle first, usually the SB, and then stent the other vessel through the first stent. This resulted in 2 layers of stent proximal to the bifurcation, full coverage of the bifurcation region and of both branches distal to the bifurcation. Because of technical complexity, high rates of procedural events, and restenosis in the BMS era, the technique was infrequently used. In the DES era, the technique was reintroduced with promising results in observational studies 16 and in the Nordic Bifurcation Study. 11 The present study recommended stenting of the MV first to avoid acute closure of the MV and showed that culotte stenting could be performed with excellent short-and medium-term results.
The crush technique, introduced by Colombo et al 14 also ensures complete lesion coverage at the SB ostium. As a modified T-stenting technique, the SB stent is deployed 2 to 3 mm proximal to the bifurcation within the MV and thereafter crushed by a stent or a balloon in the MV. The crush technique ensures flow in both MV and SB, but the 3 layers of stent proximal to the SB ostium has been a concern. Therefore, in the present study we recommended positioning of the SB stent with its proximal end in the middle of the MV to avoid extensive areas with multiple stent layers. In registries and a randomized trial, restenosis rates of 12% to 28% have been reported after crush stenting. 5, 19 Our in-segment restenosis rate of 12.1% compares favorably with these results, possibly because there was a per protocol kissing balloon postdilatation. A final kissing balloon dilatation has been related to low restenosis rates in bifurcation lesions using crush and other bifurcation stenting techniques. 22
Crush Versus Culotte Bifurcation Technique
It is noteworthy that both techniques were associated with excellent clinical and angiographic results. Procedure complexity as assessed by procedure time, fluoroscopy time, and contrast use was similar in the 2 groups. There was a higher success rate of final kissing balloon dilatation in culottetreated patients, probably because rewiring and balloon insertion through stent struts are more difficult in the crush technique, where 3 layers of stent have to be crossed versus only 1 layer in the culotte technique. This might be an explanation for the higher rate of angiographic SB in-stent restenosis in the crush group. Both techniques had a very high procedural success rate without any difference between groups. This suggests that the 2 procedures are technically equally demanding and probably also reflects high operator skill and dedication. Interestingly, SB predilatation was used significantly more often in the culotte group. This may reflect that there were more SBs with significant preprocedure stenosis, or that operators were more prone to perform a proper dilatation of the SB in culotte lesions to facilitate crossing with the SB stents.
Clinical Implications
According to our results and those of others, 5, 6, 11 PCI with implantation of SES seems to be the treatment of choice in bifurcation lesions. SES in these lesions have reduced complication rates and rates of clinical and angiographic restenosis to the same level as in less complex coronary artery lesion subsets. 20 Several authors have advocated the simple strategy in percutaneous bifurcation treatment with stenting of MV and provisional SB stenting. 13 Our results do not contradict these recommendations, but show that dedicated 2-stent techniques can be used by experienced operators with excellent results. Therefore, 2-stent strategies may be considered when SB restenosis should be avoided, ie, in large SBs, where restenosis is likely to result in clinical problems.
Both the crush and the culotte bifurcation strategy were associated with excellent clinical and angiographic results. On the basis of the present study results, 1 of the 2 techniques studied cannot be claimed superior to the other. This choice should be based on operator experience and the lesion characteristics.
Study Limitations
This study had an open design with operators and patients being aware of the technique used. MACE, however, was adjudicated by a blinded event committee and should not be influenced by the open design of the study. The study was considerably underpowered given the observed MACE rate. A properly powered study would include Ͼ15 000 patients. An inclusion of this order of magnitude would not be feasible in the complex lesion subset of the present study. The patients studied were operator selected, and there was a large center difference in inclusion of patients, from less than 5% to more than 50% of eligible patients. Also, it is likely that patient selection included feasibility for both treatment modalities. Therefore, the overall recommendation from the study may not be valid for all bifurcation lesions and operators. Furthermore, although the rates of MACE and significant angiographic stenosis were low after 6 months clinical and 8 months angiographic follow-up, the durability of these results on a long-term basis is not known.
Conclusions
In conclusion, excellent 6 months clinical and 8 months angiographic results can be obtained with the crush and culotte stenting of de novo coronary artery bifurcation lesions using SES. Culotte-stented lesions tended to have lower angiographic restenosis rates making this technique an attractive bifurcation stenting technique in feasible bifurcation lesion anatomies.
The 6 months clinical results and the 8 months quantitative coronary angiography results of the trial were presented as late breaking clinical trials at the Transcatheter Cardiovascular Therapeutics meeting, October 2007 and at the annual meeting of the American College of Cardiology in Chicago, March 2008.
